Please login to the form below

Not currently logged in
Email:
Password:

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

Biomarker testing 

Japanese pharmaceutical firms Astellas, Daiichi Sankyo and Takeda have joined forces to create a comprehensive database of biomarkers from healthy adults.

Each company will collect and analyse biomarker data from healthy volunteers, pooling this for comparison with patients taking part in preclinical and clinical research.

The patient data will come from Astellas, Daiichi Sankyo and Takeda clinical studies that use protein and metabolite biomarkers that will be carried out at their respective research bases in Japan.

In a joint statement, the three companies said they intend to publicise the resulting analysis, commenting that “fundamental biomarker data from healthy adults … has not been sufficiently accumulated globally” to date.

They hope that the research collaboration will subsequently accelerate the development of innovative new medicines, particularly in Japan but also worldwide.

The collection of the data samples will be overseen by Dr Thomas Hankemeier in association with a local CRO at Leiden University in the Netherlands.

Biomarkers are naturally occurring characteristics formed from ordinary biological, pathological or physiological processes and which can be objectively measured to document pharmacological responses to therapeutic intervention.

Biomarker collaborations have become increasingly common in the industry, with AstraZeneca's new drug discovery genomics consortium also planning to publish its findings. 

Similarly in 2015 Genentech partnered with 23andMe to analyse genomic data for Parkinson's disease. 

Meanwhile, at a regulatory level, the EMA's recent draft Alzheimer's disease research guidelines looks at the need for biomarkers.

Article by
Rebecca Clifford

23rd May 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics